Ibrutinib can increase CD4+ and CD8+ numbers, reduce CLL mediated immunosuppression[122] and may enhance Th1 subtype activity and anti-parasite immunity through ITK inhibition[123]. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.